HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.
Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of beta1 integrin, a major cell-ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.
Weigelt
Britta
B
Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Mailstop 977R225A, 1 Cyclotron Road, Berkeley, CA 94720, USA. Britta.Weigelt@cancer.org.uk
Lo
Alvin T
AT
Park
Catherine C
CC
Gray
Joe W
JW
Bissell
Mina J
MJ
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018929:Cell Culture Techniques / Q000295:instrumentation; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation / Q000187:drug effects; D005109:Extracellular Matrix / Q000502:physiology; D005260:Female; D005782:Gels; D006801:Humans; D019012:Integrin beta1 / Q000502:physiology; D007797:Laminin / Q000494:pharmacology; D000077341:Lapatinib; D009363:Neoplasm Proteins / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D005782:Gels; D019012:Integrin beta1; D007797:Laminin; D000077341:Lapatinib; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1943-8
12576544
Oncogene. 2007 May 28;26(25):3637-43
17530017
Oncogene. 2009 Jan 22;28(3):461-8
18978815
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
In Vitro Cell Dev Biol. 1987 Mar;23(3):181-8
3558253
Matrix Biol. 2008 Jul;27(6):573-585
18411046
Cold Spring Harb Symp Quant Biol. 2005;70:343-56
16869771
Cancer Cell. 2002 Sep;2(3):205-16
12242153
Nat Methods. 2007 Apr;4(4):359-65
17396127
Cancer Cell. 2006 Dec;10(6):515-27
17157791
Oncogene. 2007 Nov 1;26(50):7163-9
17525746
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6
9843973
Mol Oncol. 2007 Jun;1(1):84-96
18516279
Development. 1989 Feb;105(2):223-35
2806122
Cancer Cell. 2004 Aug;6(2):159-70
15324699
J Cell Biol. 2004 Feb 16;164(4):603-12
14769856
Science. 1995 Feb 10;267(5199):891-3
7531366
Science. 1987 Jan 9;235(4785):177-82
3798106
Cancer Res. 2008 Jun 1;68(11):4398-405
18519702
Cancer Res. 2005 Dec 1;65(23):10992-1000
16322248
Biochem Cell Biol. 1996;74(6):833-51
9164652
J Mammary Gland Biol Neoplasia. 2003 Oct;8(4):395-408
14985636
Cell. 2007 Aug 24;130(4):601-10
17719539
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8
1384042
Annu Rev Cell Dev Biol. 2006;22:287-309
16824016
Semin Cancer Biol. 2008 Oct;18(5):311-21
18455428
Science. 1999 Aug 13;285(5430):1028-32
10446041
J Cell Biol. 1997 Apr 7;137(1):231-45
9105051
Biomaterials. 2005 Mar;26(9):979-86
15369686
Curr Opin Cell Biol. 2003 Dec;15(6):753-62
14644202
Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45
17684528
J Cell Biol. 2009 Jan 12;184(1):57-66
19139262
J Mammary Gland Biol Neoplasia. 1998 Apr;3(2):201-13
10819528
Cancer Res. 1999 Apr 1;59(7 Suppl):1757-1763s; discussion 1763s-1764s
10197593
Cancer Res. 2008 Nov 15;68(22):9221-30
19010894
Cancer Cell. 2004 Aug;6(2):117-27
15324695
Nat Rev Cancer. 2001 Oct;1(1):46-54
11900251
N Engl J Med. 2005 Oct 20;353(16):1673-84
16236738
Cancer Res. 2006 Feb 1;66(3):1526-35
16452209